International study for treatment of relapsed high risk childhood ALL (HR-ALL)

  • Strong, Robyn (Project Manager)
  • Revesz, Tamas (Primary Chief Investigator (PCI))
  • Sutton, Rosemary (Chief Investigator (CI))
  • Lock, Richard B (Chief Investigator (CI))
  • Trahair, Toby (Chief Investigator (CI))
  • Dalla Pozza, Luciano (Chief Investigator (CI))
  • Downie, Peter, Monash Children's Hospital (Chief Investigator (CI))
  • Osborn, Michael (Chief Investigator (CI))
  • Jones, Janelle (Chief Investigator (CI))

Project: Research

Project Details

Project Description

Randomised Phase II trial to improve the outcomes of children and adolescents diagnosed with ALL with a high risk first relapse by determining if the addition of a new therapeutic agent (Bortezomib) to the standard chemotherapy treatment protocol (ALL-R3) will improve rates of subsequent relapses and provide effective disease control in children with HR-ALL.
Short titleIntReALL HR
AcronymIntReALL HR
Effective start/end date1/10/1831/08/22


  • Kids' Cancer Project: A$416,422.00